EUVIMEDEUVIMED entdecken
Multizentrische Studie

Clinical Utility of Genetic Variants in PNPLA3 and TM6SF2 to Predict Liver‐Related Events in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Yuya Seko iD, Kanji Yamaguchi iD, Toshihide Shima, Michihiro Iwaki, Hirokazu Takahashi, Miwa Kawanaka, Saiyu Tanaka, Yasuhide Mitsumoto, Masato Yoneda, Atsushi Nakajima, Takeshi Okanoue iD, Yoshito Itoh

Liver International · 2025-04 · 45 (4)

DOI: 10.1111/liv.16124 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Liver International, online erschienen am 07.10.2024. Verfasst von Yuya Seko und 11 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Lipase, Membrane Proteins, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, Ministry of Education, Culture, Sports, Science and Technology, Takeda Japan Medical Funded Research Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Fibrosis‐4 (FIB‐4) index and genetic polymorphisms have been used in assessing the risk of liver‐related events (LRE) in metabolic dysfunction‐associated steatotic liver disease (MASLD). To establish a more efficient prediction strategy for LRE, we investigated a combined approach that uses the FIB‐4 index and genetic polymorphisms.

Methods

We enrolled 1304 Japanese patients with biopsy‐proven MASLD in this longitudinal multicenter cohort study. PNPLA3, TM6SF2, GCKR and MBOAT7 genotypes were genotyped, and polygenic risk score high fat content (PRS‐HFC) were calculated.

Results

During the follow‐up period of 8.1 year, 96 LRE occurred and 53 patients died. PNPLA3 , TM6SF2 and GCKR genotypes were associated with LRE development. We divided patients into three groups based on the FIB‐4 index and PNPLA3 and TM6SF2 genotype. The cumulative LRE development rate in each group was 2.1%/28.9%/53.5%, respectively, at 10 years. Multivariate analysis revealed hazard ratios (HRs) for LRE of 10.72 in the high‐risk group and 4.80 in the intermediate‐risk group. Overall survival in each group was 98.8%/85.2%/72.4%, respectively, at 10 years. HRs for prognosis were 8.74 in the high‐risk group and 5.62 in the intermediate‐risk group. Patients with FIB‐4 index > 2.67 and high PRS‐HFC had HR of 6.70 for LRE development and HR of 6.07 for prognosis compared to patients with FIB‐4 ≤ 2.67.

Conclusions

The approach of measuring the FIB‐4 index first followed by assessment of genetic polymorphisms efficiently detected patients at high risk of developing LRE. Therefore, this two‐step strategy could be used as a screening method in large populations of patients with MASLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LipaseMembrane ProteinsNon-alcoholic Fatty Liver DiseaseAdultAgedFemaleHumansMaleMiddle AgedGenetic Predisposition to DiseaseGenotypeJapanLongitudinal StudiesRisk FactorsAcyltransferasesAdaptor Proteins, Signal TransducingPhospholipases A2, Calcium-Independent

Stichwörter der Autor:innen

PNPLA3TM6SF2FIB‐4 indexMASLDpolygenic risk score

Substanzen

GCKR protein, humanLipaseMBOAT7 protein, humanMembrane ProteinsPNPLA3 protein, humanTM6SF2 protein, humanAcyltransferasesAdaptor Proteins, Signal TransducingPhospholipases A2, Calcium-Independent

Autor:innen und Institutionen

  • Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital, Suita, Japan.
  • Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Liver Center, Saga University Hospital, Saga, Japan.
  • General Internal Medicine 2, General Medical Center, Kawasaki Medical School, Okayama, Japan.
  • Center for Digestive and Liver Diseases, Nara City Hospital, Nara, Japan.

ORCID-Profile: Yuya Seko, Kanji Yamaguchi, Takeshi Okanoue

Förderung

  • Japan Agency for Medical Research and Development
  • Ministry of Education, Culture, Sports, Science and Technology
  • Takeda Japan Medical Funded Research Grant

Zitieren

APA

Seko, Y., Yamaguchi, K., Shima, T., Iwaki, M., Takahashi, H., Kawanaka, M., Tanaka, S., Mitsumoto, Y., Yoneda, M., Nakajima, A., Okanoue, T., & Itoh, Y. (2025). Clinical Utility of Genetic Variants in PNPLA3 and TM6SF2 to Predict Liver‐Related Events in Metabolic Dysfunction‐Associated Steatotic Liver Disease. Liver International, 45(4). https://doi.org/10.1111/liv.16124

Vancouver

Seko Y, Yamaguchi K, Shima T, Iwaki M, Takahashi H, Kawanaka M, et al. Clinical Utility of Genetic Variants in PNPLA3 and TM6SF2 to Predict Liver‐Related Events in Metabolic Dysfunction‐Associated Steatotic Liver Disease. Liver International. 2025;45(4). doi:10.1111/liv.16124

BibTeX
@article{Seko2025,
  author = {Seko, Yuya and Yamaguchi, Kanji and Shima, Toshihide and Iwaki, Michihiro and Takahashi, Hirokazu and Kawanaka, Miwa and Tanaka, Saiyu and Mitsumoto, Yasuhide and Yoneda, Masato and Nakajima, Atsushi and Okanoue, Takeshi and Itoh, Yoshito},
  title = {Clinical Utility of Genetic Variants in PNPLA3 and TM6SF2 to Predict Liver‐Related Events in Metabolic Dysfunction‐Associated Steatotic Liver Disease},
  journal = {Liver International},
  year = {2025},
  volume = {45},
  number = {4},
  doi = {10.1111/liv.16124}
}
Kostenlos starten →